论文部分内容阅读
重症病毒性肝炎(以下简称重症肝炎)是国家科委“六、五”及“七、五”重点攻关课题。全国重症肝炎攻关组(上海第二医科大学附属瑞金医院、天津市传染病医院、中国医科大学、重庆医科大学四单位组成)于“六、五”攻关期间,共收治了经肝活检病理证实的重症肝炎121例,应用共同制订的以胰高糖素—胰岛素、小牛胸腺肽、肝病用复方氨基酸、新鲜血浆为主体的新的综合疗法,取得了较好的疗效,病死率降至54.54％,但仍有半数左右病例死亡。
Severe viral hepatitis (hereinafter referred to as severe hepatitis) is the national science and technology committee “six, five” and “seven, five” key research topics. National severe hepatitis research group (Shanghai Second Medical University affiliated Ruijin Hospital, Tianjin Infectious Diseases Hospital, China Medical University, Chongqing Medical University, four units) in the “six or five” research period, were admitted to the biopsy confirmed by liver biopsy 121 cases of severe hepatitis, the use of jointly developed with glucagon - insulin, calf thymus, liver disease with compound amino acids, fresh plasma as the main body of a new comprehensive treatment, and achieved good results, the mortality rate dropped to 54.54% However, about half of the cases still die.